Sirolimus is under clinical development by AI Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sirolimus’s likelihood of approval (LoA) and phase transition for Bronchiolitis Obliterans took place on 08 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sirolimus Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sirolimus overview

Sirolimus is under development for the treatment of bronchiolitis obliterans post lung transplant, tuberous sclerosis complex and pulmonary sarcoidosis. The drug candidate is administered through inhalational route. It targets mammalian target of rapamycin (mTOR).

The drug candidate was under development for the treatment of lymphangioleiomyomatosis (LAM) and pulmonary arterial hypertension.

AI Therapeutics overview

AI Therapeutics, formerly LAM Therapeutics, is a biopharmaceutical company that identifies and develops treatments for neurological disease and cancers. It is investigating LAM-001 program against pulmonary sarcoidosis; and bronchiolitis obliterans disease caused after lung transplantation resulting in obstruction of the smallest airways of the lungs. The company is also evaluating AIT–101 drug to treat amyotrophic lateral sclerosis; and AIT-102 for rare diseases. AI Therapeutics is headquartered in Guilford, Connecticut, the US.

Quick View Sirolimus LOA Data

Report Segments
  • Innovator
Drug Name
  • Sirolimus
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Cardiovascular
  • Genetic Disorders
  • Immunology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.